| 28.22 -0.22 (-0.77%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.8 | 1-year : | 39.48 |
| Resists | First : | 28.94 | Second : | 33.8 |
| Pivot price | 26.17 |
|||
| Supports | First : | 26.25 | Second : | 24.6 |
| MAs | MA(5) : | 27.44 |
MA(20) : | 26.22 |
| MA(100) : | 25.52 |
MA(250) : | 24.79 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 89.2 |
D(3) : | 80.1 |
| RSI | RSI(14): 59.6  |
|||
| 52-week | High : | 31.34 | Low : | 16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ZYME ] has closed below upper band by 6.6%. Bollinger Bands are 11.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.9 - 29.05 | 29.05 - 29.14 |
| Low: | 27.06 - 27.24 | 27.24 - 27.36 |
| Close: | 27.94 - 28.23 | 28.23 - 28.42 |
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Sat, 24 Oct 2026
Zymeworks (ZYME) Reports Strong Phase 1 Results for ZW191 in Ova - GuruFocus
Sat, 24 Oct 2026
Zymeworks early-stage results on ADC show anti-tumor activity in ovarian cancer - Seeking Alpha
Sat, 24 Oct 2026
Zymeworks reports trial results for ovarian cancer drug ZW191 - Investing.com
Fri, 23 Oct 2026
Jefferies raises Zymeworks stock price target on Roche deal - Investing.com
Fri, 23 Oct 2026
Zymeworks Inc. Estimates – NASDAQ:ZYME - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 98.9 (%) |
| Shares Short | 5,290 (K) |
| Shares Short P.Month | 4,720 (K) |
| EPS | -2.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | 0 % |
| Operating Margin | -919 % |
| Return on Assets (ttm) | -24.2 % |
| Return on Equity (ttm) | -72.4 % |
| Qtrly Rev. Growth | -90.6 % |
| Gross Profit (p.s.) | -1.29 |
| Sales Per Share | 0.52 |
| EBITDA (p.s.) | -2.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -119 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -13.98 |
| PEG Ratio | 0 |
| Price to Book value | 25.19 |
| Price to Sales | 54.11 |
| Price to Cash Flow | -16.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|